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Abstract
Background and purpose Neurofilament light chain (NfL) is a marker of neuroaxonal damage. We aimed to study associa-
tions between serum NfL (sNfL) concentrations at different time points after ischemic stroke and outcomes.
Methods We prospectively included ischemic stroke cases (n = 595, mean age 59 years, 64% males) and assessed outcomes 
by both the modified Rankin Scale (mRS) and the NIH stroke scale (NIHSS) at 3 months and by mRS at 2 years. In a subsam-
ple, long-term (7-year) outcomes were also assessed by both mRS and NIHSS. We used the ultrasensitive single-molecule 
array assay to measure sNfL in the acute phase (range 1–14, median 4 days), after 3 months and 7 years in cases and once 
in controls (n = 595).
Results Acute-phase sNfL increased by the time to blood-draw and highest concentrations were observed at 3 months post-
stroke. High sNfL associated to stroke severity and poor outcomes, and both associations were strongest for 3-month sNfL. 
After adjusting for age, previous stroke, stroke severity, and day of blood draw, 3-month sNfL was significantly associated 
to both outcomes at all time points (p < 0.01 throughout). For all main etiological subtypes, both acute phase and 3-month 
sNfL were significantly higher than in controls, but the dynamics of sNfL differed by stroke subtype.
Conclusions The results from this study inform on sNfL in ischemic stroke and subtypes over time, and show that sNfL 
predicts short- and long-term neurological and functional outcomes. Our findings suggest a potential utility of sNfL in 
ischemic stroke outcome prediction.
Keywords Biomarkers · Cerebrovascular disease · Prognosis · Stroke in young adults
Introduction
Serum neurofilament light chain (sNfL) has recently been 
suggested as a marker of neuroaxonal injury after ischemic 
stroke with potential applications both for patient monitoring Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0041 5-019-09477 -9) contains 
supplementary material, which is available to authorized users.
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and for observational and interventional studies [1]. NfL is a 
neuron-specific structural protein [2] and cerebrospinal fluid 
concentrations can be used as markers of neuronal damage 
[3]. The recent development of methods to quantify NfL in 
serum has led to several reports on sNfL in neurodegenera-
tive disorders and traumatic brain injury [4–6] and opens 
the door for large studies on NfL as a marker of neuronal 
damage also in diseases where lumbar puncture is not part 
of the clinical routine, such as stroke. However, data on 
sNfL in ischemic stroke are still limited to a few published 
studies [1, 7–9]. Consistent with what would be expected 
of a marker of neuronal damage, results from these studies 
show higher sNfL in patients with acute ischemic stroke 
compared to both patients with a recent transient ischemic 
attack [8, 9] and controls [1, 7], and correlations between 
sNfL and infarct volume have been observed [1, 7]. There 
is evidence that sNfL increases with the time from symptom 
onset to blood-draw [1, 7, 8], and that sNfL remains elevated 
at 3 months post-stroke [1, 7]. Furthermore, recent data indi-
cate that sNfL measured at day 7 after symptom onset, but 
not as early as within 24 h, is independently associated with 
3-month functional outcome [1, 9], illustrating that the time 
point of measurement is of great importance when evaluat-
ing sNfL post-stroke.
Although reported data show promising results for sNfL 
as a biomarker in stroke, the post-stroke temporal profile 
and prognostic value remain to be evaluated in large samples 
also enabling analyses of relevant subgroups. In light of this, 
we aimed to explore sNfL in ischemic stroke in a longitu-
dinal manner and to study associations for sNfL at different 
time points after ischemic stroke to both functional and neu-
rological outcomes. We hypothesized that sNfL measured 
in the subacute or convalescent phase predicts post-stroke 
outcomes, and that the concentrations and/or the time profile 
of sNfL differ between etiologic subtypes.
Materials and methods
Study population
The study sample comprised of participants from the 
prospective Sahlgrenska Academy Study on Ischemic 
Stroke (SAHLSIS), which consecutively recruits patients 
with acute ischemic stroke aged 18–69 years at 4-stroke 
units, and has been described elsewhere [10]. The pre-
sent study included cases recruited in a phase of the study 
when serum was biobanked (1998–2003, n = 600). Acute 
ischemic stroke was defined as an episode of focal neu-
rological deficits with acute onset and lasting > 24 h and 
with no signs of hemorrhage on acute brain neuroimaging. 
All cases underwent computer tomography (CT) of the 
brain, and 65% also underwent magnetic resonance imag-
ing (MRI) in the acute phase. Cases were subsequently 
excluded if further evaluation showed another etiology of 
the presenting symptoms than stroke.
We also included controls that had been randomly 
selected from population registers to match the cases 
with regards to age, sex and geographical residence area, 
as described [10]. Controls participated in a study visit, 
and only individuals with no history of stroke, coronary 
heart disease or peripheral arterial disease and/or signs of 
ischemic heart disease on resting electrocardiogram (ECG) 
were included (n = 600). Details on the selection of con-
trols are described in the Supplemental Methods (online 
resource 1).
Baseline characteristics, stroke severity, subtypes, 
and recurrent stroke
Information on cardiovascular risk factors, cardiovascu-
lar comorbidities, and recurrent strokes was collected as 
described in the Supplemental Methods (online resource 
1). To obtain information on neurological comorbidities 
we used overlapping methods. First, we used information 
from a question on comorbidity that was included in a 
questionnaire distributed to all participants at baseline and 
to cases participating in the 7-year follow-up. Through this 
approach we identified one patient with self-reported mul-
tiple sclerosis and one with Parkinson’s disease. Addition-
ally, we searched the Swedish Hospital Discharge register 
between 1998–2011, thus including the total follow-up 
period for all participants, for ICD-10 codes G10–G14, 
G20–G26, G30–G32, and G35–G37. Participants with 
a neurological disease with probable influence on sNfL 
measurement or outcome assessment (within 1 year from 
assessment) were identified as follows: 5 patients with 
the diagnoses G209, G255, G258, G300 or G328, and 2 
controls with the diagnoses G209 or G258. Thus, in total 
seven patients and two controls were identified with a neu-
rological comorbidity. Index stroke severity was scored 
as maximum severity within the first 7 days using the 
Scandianvian Stroke Scale (SSS). We converted the SSS 
to the more commonly used NIH stroke scale (NIHSS) 
using an algorithm [11]. Etiological subtypes were clas-
sified according to the Trial of Org 10172 in Acute Treat-
ment (TOAST) criteria [12] with minor modifications as 
described [10]. According to this classification crypto-
genic stroke is defined as a non-lacunar stroke with no 
identified etiology despite complete evaluation. Thus, this 
definition is similar to the definition of embolic stroke 
of undetermined source (ESUS) in recent randomized tri-
als, for further information please see the Supplemental 
Methods (online resource 1). Patients were also subdivided 
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according to the Oxfordshire Community Stroke Project 
(OCSP) classification [13].
Outcomes at 3 months and 2 years
All cases were invited to a 3-month follow-up visit. A stroke 
neurologist (KJ) assessed functional outcome by the modi-
fied Rankin Scale (mRS) and scored neurological deficit 
(SSS converted to NIHSS as described above). After 2 years 
mRS was scored again through a telephone interview by a 
study nurse (IE) trained in stroke medicine and specifically 
trained to score the mRS by the same stroke neurologist who 
performed the 3-month follow-up.
Substudy on long‑term outcomes
Cases recruited at one of the stroke units, the main center 
at the Sahlgrenska University Hospital, who were alive at 
7 years (n = 358 out of 411) were invited to a long-term 
follow-up visit, and 296 (83%) participated. Reasons for 
drop-outs have been described in detail elsewhere [14]. The 
same study nurse (IE) scored mRS and a stroke neurologist 
scored NIHSS. For 7-year mRS and NIHSS analyses, cases 
were limited to those with available 3-month sNfL meas-
urements. For NIHSS, 272 individuals were included (n = 5 
missing NIHSS scores and n = 19 missing 3-month sNfL 
data). Among surviving participants, data for analyzing 
mRS data were missing from 19 individuals (n = 3 missing 
mRS and n = 16 missing 3-month sNfL). For the analyses 
of mRS we also included individuals who had died during 
follow-up. Of the 53 individuals who had died, sNfL was 
available in 43, bringing the total substudy count for 7-year 
mRS to 320 individuals.
Blood sampling and sNfL measurement
We collected blood samples, as described in the Supplemental 
Methods (online resource 1), from patients in the acute phase 
[median 4 days after index stroke, interquartile range (IQR) 
3–6], at 3 months (median 101 days, IQR 94–111), and at 
7 years (median 7.5 years, IQR 7.4–7.6) after index stroke. 
With regard to the acute phase, 80% of the cases were sampled 
within 6 days from stroke onset, and the numbers of cases that 
were sampled at different time points are displayed in Supple-
mental Fig. 1 (online resource 1). Controls were sampled once 
at inclusion. All samples were aliquoted and stored at − 80 °C 
pending analysis. sNfL concentrations were measured using a 
homebrew assay on the single-molecule array (SiMoA) plat-
form (Quanterix, Lexington, MA) [15], as described [4]. The 
analyses were performed by board-certified laboratory techni-
cians who were blind to clinical information, and all samples 
were analyzed on the same occasion with the same batch of 
reagents. The lower limit of quantification was 6.7 pg/mL. The 
intra-assay coefficient of variation was 6.4% for quality control 
(QC) samples with concentrations of 12.4 pg/mL and 110 pg/
mL (no difference between the low and high QC sample in this 
study). The success rate for NfL measurements was > 99%.
Statistical analyses
Functional outcome was assessed as a binary outcome (mRS 
score 0–2 vs 3–6), and the NIHSS score was treated as a 
numeric scale. For all statistical tests sNfL concentrations 
were  log10 transformed. Baseline characteristics were com-
pared using the χ2 test for proportions and Student’s t test 
or Mann–Whitney U test for numeric variables. Correla-
tions were assessed by Pearson’s correlation coefficients. 
Associations between sNfL and day of blood sampling were 
analyzed by linear regression with stroke severity (baseline 
NIHSS) and age as covariates. Linear regression was used 
to analyze associations between sNfL and stroke severity 
and neurological outcome (NIHSS). Associations between 
sNfL and functional outcome (mRS) were analyzed by 
logistic regression. All regression analyses of associations 
to outcomes were performed univariably as well as adjusted 
for age, previous stroke (before index stroke) and stroke 
severity. Analyses including acute phase and 3-month sNfL 
were additionally adjusted for day of blood sampling during 
the acute phase and at 3-month follow-up, respectively. To 
assess the diagnostic accuracy of sNfL for discriminating 
good (mRS ≤ 2) and poor (mRS > 2) outcomes, we calcu-
lated the area under the receiver operating characteristics 
(ROC) curve.
sNfL in cases and controls were compared by Student’s 
paired t test and in multivariable analyses by mixed models 
using the paired sNfL as a repeated measure and including 
hypertension, diabetes mellitus, smoking, and hyperlipi-
demia as covariates. As sNfL increases with age and con-
trols only were sampled at baseline, analyses of sNfL 7-year 
post-stroke in relation to controls were additionally adjusted 
for age. Differences in sNfL between the etiological subtypes 
were analyzed with ANCOVA adjusting for age. The decline 
in sNfL from 3 months to 7 years was compared between 
subtypes by ANOVA using age-adjusted concentrations for 
the measurement at 7 years and expressed as percent decline. 
Differences in sNfL according to OCSP subtypes were ana-
lyzed with ANOVA (post-hoc Tukey).
R 3.3.1 was used for analyzing ROC curves (package 
pROC). SPSS 20.0 was used for all other analyses. Two-
tailed p < 0.05 was considered significant. More details can 
be found in the Supplemental Methods (online resource 1).
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Results
In five patients serum was unavailable from all time points, 
leading to a study cohort of 595 patients with serum sample 
available from at least one time point and their correspond-
ing matched controls. Baseline characteristics and outcomes 
for the whole group and for the four main etiological stroke 
subtypes are shown in Table 1. As expected, the proportion 
of participants with cardiovascular risk factors and cardio-
vascular comorbidities was higher in cases than in controls. 
In cases, there were correlations between sNfL and stroke 
severity (r = 0.38 and r = 0.56 for acute phase and 3-month 
sNfL, respectively). sNfL was also correlated to age in con-
trols (r = 0.50), whereas all other correlations between sNfL 
and baseline characteristics were weak, |r| ≤ 0.2. Baseline 
characteristics for the subgroup who participated in the 
7-year follow-up are shown in Supplemental Table 1 (online 
resource 1).
Serum NfL concentrations vary over time after acute 
ischemic stroke
Concentrations of sNfL were determined in 489 and 546 
stroke cases in the acute phase and at 3 months, respectively. 
From 1998 to 2000, serum was not collected in the acute 
phase, explaining the majority (n = 78) of the missing val-
ues. Acute phase sNfL increased with time to blood-draw 
(r = 0.32), Fig. 1a. This association remained after adjust-
ment for age and stroke severity in a linear regression model 
(p < 0.001). With regards to 3 months, sNfL decreased 
slightly with the time to blood sampling (r = − 0.08), Fig. 1b. 
This association was significant in a linear regression model 
adjusting for age and stroke severity (p < 0.01).
Distributions of sNfL for the whole group are displayed 
in Fig. 2a. Acute phase and 3-month concentrations were 
correlated (r = 0.65), but 3-month sNfL was significantly 
higher than acute phase sNfL (p < 0.001). For all cases who 
had measurements of sNfL at both time points, the indi-
vidual sNfL levels are displayed in Supplemental Fig. 2 
(online resource 1), also illustrating the influence of the day 
of acute blood sampling. Although mean sNfL was highest 
at 3 months, the figure also shows that there was individual 
variability. In the group of cases with early blood sampling 
during the acute phase, a larger proportion had highest sNfL 
at 3 months compared to in the group with late acute sam-
pling. Concentrations of sNfL from the 7-year follow-up 
visit were available for 221 individuals. Distributions of 
sNfL for these cases and their matched controls are dis-
played in Fig. 2b. Also in this subgroup we detected highest 
concentrations at 3 months post-stroke.
Serum NfL is associated with stroke outcomes
Since our results indicate that the post-stroke peak sNfL 
concentrations in our study is best captured by the 3-month 
sample, we primarily assessed the association between 
3-month sNfL and outcomes. High 3-month sNfL was 
strongly associated both with poor neurological out-
come, i.e., high NIHSS score, at the 3-month follow-up 
and with poor functional outcome, i.e., mRS > 2, at both 
3 months and 2 years (Table 2). In the substudy on long-
term (7-year) outcomes, high sNfL was also significantly 
associated with both NIHSS and mRS (Table  3). All 
associations between 3-month sNfL and outcomes were 
independent of age, history of stroke, stroke severity and 
day of 3-month blood draw (Tables 2, 3). After exclusion 
of participants who experienced a recurrent stroke dur-
ing follow-up, all associations where slightly attenuated, 
but retained (e.g., OR for poor functional outcome 19.0, 
12.2 and 5.7 per log unit increase in sNfL at the 3-month, 
2-year and 7-year follow-up, respectively, p < 0.001 for 
all three).
The associations between acute phase sNfL and outcomes 
were generally weaker than those for 3-month sNfL. These 
results are displayed in the Supplemental Tables 2 and 3 
(online resource 1). The associations with 3-month func-
tional outcome was similar for cases with early (≤ day 4) vs 
late (> day 4) blood sampling during the acute phase. For 
cases with very early blood sampling (day 1, n = 24) there 
was no significant association to 3-month mRS in univari-
able analysis. Since an association to 3-month mRS has been 
previously reported for sNfL at day 7 post-stroke [1], we 
also analyzed cases with acute blood sampling at day 6–8 
(n = 129) separately. A univariable association was found, 
that was not retained after adjustment for age, previous his-
tory of stroke and stroke severity OR 2.2 (0.4–10.5).
Excluding patients with a neurological comorbidity 
yielded similar results for all outcome analyses (data not 
shown).
We next evaluated the diagnostic accuracy of sNfL for 
predicting functional outcome (mRS 0–2 vs 3–6) at 2 years 
post-stroke. Acute phase and 3-month sNfL yielded an AUC 
of 0.68 (95% CI 0.63–0.74) and 0.79 (95% CI 0.74–0.84), 
respectively. For comparison, the corresponding AUC for 
baseline stroke severity, a well-known strong predictor, was 
0.84 (95% CI 0.80–0.88). Including age, sex, hypertension, 
diabetes mellitus, and smoking, in addition to baseline stroke 
severity, in the same model yielded an AUC of 0.86 (95% CI 
0.82–0.89). When adding 3-month sNfL to the latter model, 
the AUC increased slightly, but not significantly to 0.87 
(95% CI 0.84–0.90). The corresponding AUCs for 7-year 
mRS were for acute phase and 3-month sNfL 0.69 (95% CI 
0.62–0.76) and 0.73 (95% CI 0.67–0.79), respectively; and 
for baseline stroke severity 0.76 (95% CI 0.70–0.81). For 
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Table 1  Baseline characteristics, sNfL concentrations, stroke severity (NIHSS baseline) and stroke outcomes (NIHSS and mRS) for the study 
participants
Data are shown as median and interquartile range (IQR) or number (n) and percentage for controls and for the whole group of ischemic stroke 
cases as well as for the four major ischemic stroke subtypes. The remaining cases were of either other determined cause (n = 51) or undetermined 
cause (n = 91). Differences compared to the control group were examined using the χ2-test for proportions and Mann–Whitney U test for continu-
ous variables, except for sNfL concentrations that were examined with paired t test on log-transformed sNfL values
NIHSS NIH stroke scale, mRS modified Rankin Scale, sNfL serum neurofilament light chain
*p < 0.05, **p < 0.01, ***p < 0.001
a Please note that the 7-year data are from a substudy including a subset of cases from the main study
Controls (n = 595) Cases (n = 595) Large vessel dis-
ease (n = 72)
Small vessel dis-
ease (n = 123)
Cardioembolic 
stroke (n = 97)
Cryptogenic 
stroke (n = 161)
Age, median (IQR) 59 (52–65) 59 (52–65) 60 (57–65) 60 (54–64) 61 (54–66) 56 (48–62)***
Male sex, n (%) 382 (64) 382 (64) 53 (74) 76 (62) 66 (68) 95 (59)
Hypertension, n (%) 220 (37) 350 (59)*** 43 (60)*** 88 (72)*** 49 (51)** 87 (54)***
Diabetes mellitus, 
n (%)
33 (6) 112 (19)*** 24 (33)*** 26 (21)*** 19 (20)*** 22 (14)***
Hyperlipidemia, 
n (%)
398 (67) 413 (69)** 53 (74)* 77 (63) 73 (75)** 107 (66)
Current smoker, 
n (%)
108 (18) 230 (39)*** 39 (54)*** 53 (43)*** 33 (34)*** 59 (37)***
Previous history of 
stroke, n (%)
0 (0) 114 (19)*** 21 (30)*** 25 (20)*** 22 (23)*** 18 (11)***
History of coronary 
artery disease, n 
(%)
0 (0) 101 (17)*** 16 (22)*** 9 (7)*** 39 (40)*** 16 (9)***
Statins at 3 months, 
n (%)
31 (5) 198 (33)*** 36 (50)*** 40 (33)*** 32 (33)*** 55 (34)***
Anti-hypertensive 
drugs at 3 months, 
n (%)
87 (15) 290 (49)*** 35 (49)*** 70 (57)*** 64 (66)*** 61 (38)***
Anticoagulant drugs 
at 3 months, n (%)
0 111 (19)*** 8 (11)*** 2 (2)** 60 (62)*** 17 (11)***
NIHSS score base-
line, median (IQR)
NA 2.9 (1.6–7.2) 3.3 (1.2–11.5) 2.5 (1.6–4.2) 3.8 (1.2–11.1) 2.5 (1.2–6.5)
NIHSS score 
3 months, median 
(IQR)
NA 0.4 (0.4–1.9) 1.2 (0.4–2.7) 0.4 (0.4–1.5) 0.8 (0.4–2.7) 0.4 (0.4–1.9)
NIHSS score 
7 years, median 
(IQR)a
NA 0 (0–2) 1 (0–5) 0 (0–1) 0 (0–4) 0 (0–1)
mRS score 
3 months, median 
(IQR)
NA 2 (1–2) 2 (1–3) 1 (1–2) 2 (1–3) 2 (1–2)
mRS score 2 years, 
median (IQR)
NA 2 (1–2) 2 (1–3) 1 (1–2) 2 (1–3) 2 (1–2)
mRS score 7 years, 
median (IQR)a
NA 2 (1–4) 3 (2–6) 2 (0–3) 3 (2–6) 2 (1–3)
sNfL acute (pg/mL), 
median (IQR)
14.2 (9.7–21) 60.2 (28.3–
190.4)***
133.4 (54.7–
395.5)***
33.3 (18–70.3)*** 101.2 (43.4–
324.3)***
51.6 (26.2–
155.7)***
sNfL 3 months 
(pg/mL), median 
(IQR)
NA 90.6 (41.8–
230.3)***
190 (70.3–
336.7)***
55.6 (28.6–
109.6)***
136 (59.6–
390.9)***
81.9 (36.2–
215.4)***
sNfL 7 years (pg/
mL), median 
(IQR)a
NA 18.1 (11.5–
35.5)***
22.0 (14.5–39.9)** 23.8 (13.1–39.6)** 21.0 (17.6–
23.4)**
17.3 (11.3–
28.9)***
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clinical variables and baseline stroke severity the AUC was 
0.81 (95% CI 0.76–0.86), which was similar when adding 
3-month sNfL to the model. Receiver operating characteris-
tics curves for the 2-year and 7-year outcomes are displayed 
in Supplemental Figs. 3 and 4 (online resource 1). AUCs 
for acute phase sNfL and 3-month mRS are displayed in the 
Supplemental results (online resource 1).
Serum NfL is higher in cases than in controls 
and differs by etiologic subtype
We also measured sNfL in all 595 controls, and sNfL was 
higher in cases compared to controls both in the acute phase 
and 3 months post-stroke (Table 1). After adjustment for 
cardiovascular risk factors, the difference between cases 
and controls was retained for both time points [the ratio of 
sNfL in cases vs controls was 5.0 (95% CI 4.4–5.9) for the 
acute phase and 6.5 (6.0–7.2) for 3-month concentrations]. 
Exclusion of participants who experienced a recurrent stroke 
within 3 months yielded similar results for 3-month sNfL 
[6.2 (5.4–6.9)]. After 7 years sNfL had declined, but was 
still significantly higher than in controls. However, this dif-
ference was not retained when adjusting for age and cardio-
vascular risk factors (ratio of sNfL in cases vs controls, 1.1, 
95% CI 1.0–1.3). Excluding participants with neurological 
comorbidities yielded similar results as described above for 
all time points (data not shown).
sNfL in the four main etiologic subtypes is presented 
in Table 1, and the distributions of sNfL are displayed 
in Fig. 3. sNfL concentrations were significantly higher 
a b
Fig. 1  Correlations between sNfL and day of blood sampling during the acute phase (r = 0.32, p < 0.001, a) and at 3-month follow-up after 
ischemic stroke (r = −  0.08, p = 0.06, b). sNfL serum neurofilament light chain
Fig. 2  sNfL concentrations in 
ischemic stroke cases at differ-
ent time points post-stroke and 
in controls. a sNfL concentra-
tions in cases in the acute phase 
and at 3 months and in controls. 
b sNfL concentrations for the 
different time points for cases 
participating in the substudy on 
long-term outcomes (n = 221) 
and the matched controls 
(n = 221). Horizontal lines 
represent median concentrations 
and interquartile ranges. sNfL 
serum neurofilament light chain
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in each subtype compared to their matched controls. The 
highest acute phase and 3-month concentrations were 
observed in large vessel disease (LVD) and in cardioem-
bolic (CE) stroke. At the 7-year follow-up the subtype 
pattern was different with highest sNfL in small vessel 
disease (SVD) (Fig. 3), but after adjustment for age this 
difference was not retained. The decline over time from 
3 months to 7 years differed significantly between SVD 
(63%) and each of LVD (85%), CE (84%) and cryptogenic 
stroke (80%) (p < 0.05, throughout).
Table 2  Results from regression 
analyses showing associations 
to outcomes (NIHSS and mRS) 
at 3 months and 2 years
Multivariable linear regression models were used for calculation of β, i.e., change in NIHSS at 3 months, 
per log unit increase in sNfL (one log unit represents a tenfold increase). Multivariable logistic regression 
models were used for calculation of odds ratio per log unit increase in sNfL for poor outcome (mRS > 2) at 
3 months and 2 years. For cases with 3-month sNfL measurements, 3-month NIHSS was available in 522 
cases, 3-month mRS in 532 cases, and 2-year mRS in 542 cases
sNfL serum neurofilament light chain, NIHSS NIH stroke scale, mRS modified Rankin Scale
a Adjusted for age, history of stroke, and day for blood sampling at 3-month follow-up
b Adjusted for age, history of stroke, day for blood sampling at 3-month follow-up, and baseline NIHSS
c Adjusted for age and history of stroke
d Adjusted for age, history of stroke, 3-month log sNfL and day for blood sampling at 3-month follow-up
NIHSS at 3 months mRS > 2 at 3 months mRS > 2 at 2 years
β 95% CI for β OR 95% CI for OR OR 95% CI for OR
Log sNfL 3 months 2.59 2.24–2.94 19.66 10.61–36.43 11.47 6.65–19.79
Log sNfL 3  monthsa 2.69 2.33–3.05 24.82 12.73–48.40 11.52 6.52–20.38
Log sNfL 3  monthsb 0.99 0.65–1.33 5.83 2.72–12.47 3.24 1.67–6.29
NIHSS score baseline 0.35 0.33–0.38 2.39 1.31–1.47 1.24 1.19–1.29
NIHSS score  baselinec 0.35 0.33–0.38 1.39 1.32–1.47 1.26 1.21–1.31
NIHSS score  baselined 0.29 0.25–0.32 1.29 1.21–1.38 1.20 1.14–1.27
Table 3  Results from regression analyses showing associations to 
outcomes (NIHSS and mRS) in the substudy assessing 7-year out-
comes
Multivariable linear regression models were used for calculation of 
β, i.e., change in NIHSS at 7 years, per log unit increase in sNfL (one 
log unit represents a tenfold increase). Multivariable logistic regres-
sion models were used for calculation of odds ratio per log unit 
increase in sNfL for poor outcome (mRS > 2) at 7 years. For 7-year 
mRS 3-month sNfL was available in 320 cases and for 7-year NIHSS 
in 272 cases
a Adjusted for age, history of stroke, and day for blood sampling at 
3-month follow-up
b Adjusted for age, history of stroke, day for blood sampling at 
3-month follow-up, and baseline NIHSS
c Adjusted for age and history of stroke
d Adjusted for age, history of stroke, 3-month log sNfL and day for 
blood sampling at 3-month follow-up
NIHSS at 7 years mRS > 2 at 7 years
β 95% CI for β OR 95% CI for OR
Log sNfL 3 months 3.82 3.11–4.53 5.55 3.31–9.29
Log sNfL 3  monthsa 3.77 3.03–4.50 6.61 3.45–10.89
Log sNfL 3  monthsb 1.76 0.91–2.60 2.86 1.45–5.65
NIHSS score baseline 0.42 0.36–0.49 1.18 1.12–1.24
NIHSS score  baselinec 0.42 0.36–0.49 1.20 1.14–1.27
NIHSS score  baselined 0.31 0.23–0.39 1.13 1.06–1.20
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Fig. 3  Distribution of sNfL concentrations in the acute phase, 
at 3  months and at 7  years in the four main etiologic subtypes of 
ischemic stroke. sNfL serum neurofilament light chain
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Serum NfL in relation to OCSP classification
Three-month sNfL differed significantly between each pair 
of the subtypes total anterior circulation infarct (TACI), par-
tial anterior circulation infarct (PACI), posterior circulation 
infarct (POCI) and lacunar infarct (LACI). The same was 
true for the acute phase concentrations except that there was 
no significant difference between PACI and POCI (p = 0.99). 
In the acute phase, the LACI group had lowest sNfL, fol-
lowed by POCI, PACI, and TACI groups in the order of 
increasing sNfL.
Discussion
In this cohort of ischemic stroke, circulating sNfL concen-
trations increased with the day of blood draw in the acute 
phase after index stroke, were highest at 3 months, and had 
declined 7 years post-stroke. sNfL at 3 months post-stroke 
showed strongest independent associations to both short- and 
long-term outcomes. Finally, we observed that the dynamics 
of sNfL differ by subtype of ischemic stroke.
For the first time we show that sNfL predicts both func-
tional and neurological outcomes both in the short- and 
long-term after overall ischemic stroke. In our cohort, asso-
ciations between acute phase and 3-month sNfL and out-
comes were independent of age and stroke severity, which 
is in line with a recent but smaller study (n = 110) with data 
on sNfL measured at day 7 from admission [1]. In contrast, 
no independent association between sNfL and 3-month 
mRS was detected when blood was drawn within 24 h from 
symptom onset [9]. Thus, according to the present and previ-
ous studies [7, 8], 24 h is too early to catch the sNfL peak. 
In a study on non-traumatic cervical artery dissection [8], 
blood was drawn at similar time points as the acute phase 
sampling in the present study, but an association between 
sNfL and 3-month mRS did not remain after adjustment for 
stroke severity [8], which could be due to the small sam-
ple size (n = 49) and the fact that the electrochemilumines-
cence immunoassay was used to measure sNfL, which is 
less sensitive compared to the method we used here [16]. 
We used the ultrasensitive SiMoA technology to measure 
sNfL levels longitudinally after stroke, and for the first time 
these were investigated in relation to outcomes measured 
by both NIHSS and mRS scores at different time points. 
These results need replication, but indicate that sNfL is a 
promising candidate for prediction of short- and long-term 
outcomes after ischemic stroke. In contrast to most previ-
ously studied biomarkers of stroke outcomes that have 
mainly focused on inflammatory and hormonal pathways, 
the neurofilament proteins are exclusively expressed in neu-
rons and thereby represent markers specific for neuroaxonal 
injury. This means they are independent of the underlying 
causal pathways and provide a measure of brain injury with 
the advantage of being much more readily available com-
pared to brain imaging techniques. However, as indicated 
above the time point of measurement seems to be crucial 
when evaluating sNfL post-stroke. The warranted next step 
is to establish the post-stroke temporal profile of sNfL. As 
discussed below, the peak is probably not fully captured in 
our or previous studies, and speculatively measurements of 
peak levels could add predictive ability of sNfL. However, 
repeated measurements might be even more valuable, by 
measuring the rates of increase and decrease in sNfL and, 
thus capturing the dynamics of post-stroke injury processes.
We observed significantly higher sNfL in ischemic 
stroke cases compared to controls in the acute phase, after 
3 months and 7 years, and this was also true when excluding 
participants with neurological comorbidities. After 7 years 
the sNfL had declined, and the association to case–control 
status was not independent of age and cardiovascular risk 
factors/comorbidities. The magnitude of the sNfL increment 
within 3 months post-stroke was associated to stroke sever-
ity, i.e., baseline NIHSS, which is in line with previous data 
[8, 9] and expected since both are measures related to the 
magnitude of brain injury. In line with this, sNfL differed 
between the OCSP subtypes with lowest acute phase levels 
in LACI. We did not have data on infarct size and localiza-
tion, but speculate that sNfL and the NIHSS score represent 
overlapping but complementary measures of the magnitude 
and functional consequences of brain damage. Furthermore, 
our results indicate that sNfL continues to increase several 
days after stroke. Similar associations between time of blood 
draw and sNfL have been reported in lacunar stroke [7], 
ischemic stroke caused by cervical artery dissection [8], 
and traumatic spinal cord injury [17]. Moreover, a recent 
study on a subgroup of patients with acute ischemic stroke 
(n = 89) who had measurements of sNfL on day 1, 2, 3, and 
7 after hospital admission observed highest concentrations 
at day 7 [1] and a study on phosphorylated neurofilament 
heavy protein observed highest concentrations at 3 weeks 
post-stroke [18]. Interestingly, a small recent study on 30 
ischemic stroke patients with repeated measurements of 
sNfL on day 0–1, 2–3, 7–9, 3 weeks and 3–5 months con-
firmed these findings with increasing sNfL during the acute 
phase and highest concentrations at 3 weeks [19]. In our 
study, sNfL 3 months post-stroke was significantly higher 
compared to the acute phase, but contrary to the acute phase, 
the 3-months concentrations were decreasing with the day 
of blood-draw. In addition, as depicted in Supplemental 
Fig. 1 (online resource 1), a larger proportion of patients 
with acute phase blood sampling ≤ 4 days post-stroke had 
higher sNfL at 3 months compared to patients with acute 
blood sampling later than 4 days post-stroke. Taken together, 
these data point towards a peak in sNfL somewhere between 
the acute phase and 3 months post-stroke. The half-life of 
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NfL in humans is not known, but data from mice have sug-
gested a half-life around 3 weeks [20]. Neurofilaments are 
abundant in large myelinated axons susceptible to Wallerian 
post-stroke degeneration and the time profile of immunohis-
tochemical as well as radiological findings after stroke show 
a delayed and longstanding degenerative process fitting the 
release pattern of sNfL in this study [21, 22]. Thus, the pro-
longed release of NfL possibly reflects these processes. This 
is further supported by recent data showing a correlation 
between sNfL measured 6 months post-stroke and a quan-
titative measure of secondary neurodegeneration obtained 
from diffusion tensor imaging MRI [1]. Although we do not 
know when sNfL is peaking after stroke, it is reasonable to 
assume that this time point may vary with infarct size. In 
support of such a hypothesis, in contrast to our results on 
all ischemic stroke and previous on lacunar stroke [7], sNfL 
in amateur boxers had decreased after a 3-month period of 
rest from boxing [5], which could be due to a milder brain 
injury compared to stroke. Taken together, present data on 
the temporal profile of sNfL post-stroke are not sufficient 
to identify the post-stroke peak. Therefore, we cannot draw 
any conclusions on the optimal time(s) for measurement, but 
clearly the very first days after stroke are too early.
We found that the sNfL profile differs by etiologic sub-
type of ischemic stroke. LVD and CE stroke showed highest 
acute phase and 3-month concentrations, which is expected 
since those etiologies in general cause larger strokes. The 
median 3-month sNfL concentrations for LVD were 190 pg/
mL, CE stroke 136 pg/mL and SVD 56 pg/mL. For com-
parison, reported sNfL concentrations were approximately 
30 pg/mL in multiple sclerosis [6], 80 pg/mL in frontotem-
poral dementia [4], and 22 pg/mL in mild traumatic brain 
injury (amateur boxers sampled 7–10 days after boxing) [5]. 
It should be noted, however, that these comparisons are only 
indicative; the assays used in these studies are similar (the 
same antibody pair to measure NfL was used) but have not 
been formally standardized to a reference material or harmo-
nized to each other. Given the promising results on NfL as 
a blood biomarker for neuronal injury, such standardization 
projects are highly warranted. At 7 years, SVD showed high-
est sNfL, although at this time point the difference between 
the subtypes was not statistically significant in our sample. 
It is plausible that the concentrations are constantly elevated 
in some patients with SVD, due to a progressive disease 
course. In line with this, previous studies on NfL in cerebro-
spinal fluid have demonstrated increased concentrations with 
increasing severity of white-matter lesions on magnetic reso-
nance imaging (MRI) [23, 24]. Moreover, a study on patients 
with small subcortical infarcts (< 25 mm) showed elevated 
sNfL in patients with new, but clinically silent cerebral small 
vessel disease-related lesions on MRI at follow-up [7]. This 
finding was further supported by a recent study showing that 
ischemic stroke patients with recurrent ischemic lesions on 
MRI at 6 months had higher sNfL compared to those with-
out new lesions [1].
Our study has several strengths. The longitudinal design 
with repeated blood-draws and assessments of outcomes 
in short- and long-term provide novel information on the 
dynamics of sNfL, its relation to ischemic stroke subtypes, 
and its potential as a predictor of ischemic stroke outcomes. 
Further, we assessed two different outcome measures. Func-
tional outcome as assessed by the mRS represents a crude 
measure, but the dichotomization refers to differences of 
great importance clinically and for the patients. The NIHSS 
assesses neurological outcome and is more detailed com-
pared to the mRS. Our study sample was large and com-
prised of consecutive, well-characterized and relatively 
young ischemic stroke patients, which is why the propor-
tion of comorbidities was low. Blood sampling was strictly 
standardized and sNfL was measured by the most sensi-
tive method available [16]. Our study also has limitations. 
Although we had serum samples available from three time 
points, and those in the first phase after stroke were spread 
over a period of time, we did not have repeated measure-
ments during the acute phase and no measurements between 
the acute phase and 3 months. Therefore, our data are insuf-
ficient to identify the post-stroke peak in sNfL. Blood sam-
pling in narrower time intervals over the first weeks and 
months is needed in future studies to determine the trajec-
tories of sNfL after stroke. Moreover, index stroke severity 
was scored as maximum severity within the first 7 days and 
it is possible that some cases, especially those with early 
blood sampling, have experienced a deterioration leading to 
falsely low sNfL concentrations in relation to stroke severity. 
Moreover, sNfL is known to associate with cerebral small 
vessel burden [25]. Since we did not have available data on 
small disease burden for all cases or any of the controls, 
we were not able to account for this in our analyses. There 
were also several years between blood sampling and sNfL 
analyses. However, all samples were stored at − 80 °C pend-
ing analysis, and NfL is known to be stable at − 80 °C and 
has also been shown to be stable over multiple freeze–thaw 
cycles [26]. Finally, our study cohort consisted of young and 
middle-aged ischemic stroke patients which may reduce the 
external validity of our results.
Conclusions
Patients with acute ischemic stroke have increased sNfL 
concentrations, and the dynamics of sNfL differ by stroke 
subtype. There is an association between sNfL and both neu-
rological and functional outcomes, which is independent of 
stroke severity. The results from this study, which repre-
sent the largest analyses of sNfL after ischemic stroke and 
also include repeated measures of both sNfL and outcomes, 
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improve our understanding of sNfL in ischemic stroke. 
Future studies should aim to establish the time profile of 
sNfL post-stroke to enable identification of the optimal time 
for measurements.
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